autolymphocyte therapy

autolymphocyte therapy

A form of immunotherapy for treating metastatic renal carcinoma, in which a patient’s leukocytes are removed, stimulated by monoclonal antibodies, causing them to produce and secrete cytokines. The cytokine supernatant is then removed and readministered to the patient. Despite early reports of success, this therapy has been discontinued.

autolymphocyte therapy

Experimental oncology A form of immunotherapy for treating metastatic renal carcinoma, in which a Pt's WBCs are removed, stimulated by monoclonal antibodies, which causes the WBCs to produce and secrete cytokines; the cytokine supernatant is then removed and readministered with an aliquot of the Pt's own WBCs. Cf Immunoaugmentive therapy.
Mentioned in ?
References in periodicals archive ?
Specifically, they aim to assess the safety and efficacy of combination therapy of gemcitabine and activated autolymphocyte therapy in patients with respectable pancreatic cancer.
Data analysis has begun on the results collected from the phase III pivotal trial of Autolymphocyte Therapy (ALT) in patients with metastatic renal cell carcinoma (kidney cancer) and is expected to continue for the next few months.
The Treatment IND program will allow autolymphocyte therapy (ALT), an immunotherapy which uses a patient's own immune cells to treat disease, to be available as a treatment option to patients with MRCC who were not able to participate in ALT clinical trials.
Specifically, the two partners have begun animal experiments to assess the efficacy of activated autolymphocyte therapy and dendritic cell therapy in the treatment of various cancers.
Cellcor, through the development of its autologous cellular therapy, known as autolymphocyte therapy (ALT), has an established Good Manufacturing Practices (GMP) manufacturing facility in Newton, Massachusetts.
For example, instead of the typical PLA/ELA process, autologous cell therapies like autolymphocyte therapy (ALT), will be reviewed under a Biologics License Application (BLA).
This increase in research and development expenses was due to increased patient enrollment in Cellcor's Pivotal Phase III trial of autolymphocyte therapy (ALT) in metastatic renal cell carcinoma (advanced kidney cancer).
This increase in research and development expenses associated with Cellcor's Pivotal Phase III trial of autolymphocyte therapy (ALT) in metastatic renal cell carcinoma (advanced kidney cancer) was offset by the receipt of a one time payment related to a corporate partnering effort.
a biotechnology company focused on the development and commercialization of autolymphocyte therapy (ALT), a proprietary immunotherapy using a patient's own immune cells to treat cancer and certain infectious diseases.
The company's proprietary cellular immunotherapy, autolymphocyte therapy (ALT), has initial application in the treatment of renal cell carcinoma (RCC) and may have potential for the treatment of other forms of cancer and serious infectious diseases.
Cellcor has recently completed the patient accrual for its Phase III pivotal trial using autolymphocyte therapy (ALT) to treat metastatic kidney cancer patients.
Cellcor is a biotechnology company focused on the development and commercialization of autolymphocyte therapy, a proprietary immunotherapy using a patient's own immune cells to treat cancer and certain infectious diseases.